Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.
Mult Scler Relat Disord
; 57: 103345, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1851824
ABSTRACT
COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection. We report clinical outcomes of 18 pwMS receiving NTZ retreatment during confirmed SARS-CoV-2 infection. No worsening of infection or recovery delay was observed. Our data supports the safety of NTZ redosing in these circumstances.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
COVID-19
/
Multiple Sclerosis
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Mult Scler Relat Disord
Year:
2022
Document Type:
Article
Affiliation country:
J.msard.2021.103345
Similar
MEDLINE
...
LILACS
LIS